There appears to be a boon coming for the Indian pharmaceutical industry from easing price pressure in the US generics market, as per reports from Phillip Capital.

The firm anticipates that pharmaceutical companies within its coverage universe will likely experience a 12% year-on-year earnings growth in the Q2.

The list includes Dr Reddy’s Laboratories (ASX:REDY), Cipla, Sun Pharmaceutical Industries, Lupin, and Zydus Lifesciences.

This prediction of growth comes backed by margin expansions and a projected 15% sales bump.

Additionally, the firm suggests that the incremental benefits from key launches will further aid the growth of U.S generics.

In particular, Lupin is predicted to lead growth with a near-three-fold jump in earnings.

Simultaneously, companies like Zydus Lifesciences, Dr Reddy’s Laboratories and Cipla are seen to continue benefiting from the sales of generic cancer drug, Revlimid.

Indeed, the Nifty Pharma index has risen by 0.72% following a gain of 13.29% in the previous quarter.

Dr Reddy’s Laboratories (ASX:REDY) is an integrated pharmaceutical company, producing a wide range of medicinal products.